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Abstract: Retinitis pigmentosa (RP) is an inherited retinal disease (IRD) with an overall prevalence of
1 in 4000 individuals. Mutations in EYS (Eyes shut homolog) are among the most frequent causes of
non-syndromic autosomal recessively inherited RP and act via a loss-of-function mechanism. In light
of the recent successes for other IRDs, we investigated the therapeutic potential of exon skipping
for EYS-associated RP. CRISPR/Cas9 was employed to generate zebrafish from which the region
encompassing the orthologous exons 37-41 of human EYS (eys exons 40-44) was excised from the
genome. The excision of these exons was predicted to maintain the open reading frame and to result
in the removal of exactly one Laminin G and two EGF domains. Although the eys∆exon40-44 transcript
was found at levels comparable to wild-type eys, and no unwanted off-target modifications were
identified within the eys coding sequence after single-molecule sequencing, Eys∆exon40-44 protein
expression could not be detected. Visual motor response experiments revealed that eys∆exon40-44
larvae were visually impaired and histological analysis revealed a progressive degeneration of the
retinal outer nuclear layer in these zebrafish. Altogether, the data obtained in our zebrafish model
currently provide no indications for the skipping of EYS exons 37-41 as an effective future treatment
strategy for EYS-associated RP.
Keywords: EYS; CRISPR/Cas9; antisense oligonucleotides; exon skipping therapy; photoreceptors;
retinitis pigmentosa; zebrafish
1. Introduction
Retinitis pigmentosa (RP) is an inherited retinal disease (IRD) with an overall preva-
lence of 1 in 4000 individuals, affecting almost 2 million individuals worldwide [1,2].
Patients present with a progressive loss of visual function caused by the degeneration of
the light-sensitive photoreceptor cells in the retina, often resulting in total blindness in the
fifth or sixth decade of life. RP typically manifests with night blindness and visual field
constriction from early adolescence onwards, followed by a gradual decrease of visual
acuity later in life. This non-congenital onset and slowly progressive nature of RP provides
ample time for therapeutic intervention.
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To date, mutations in more than 100 genes have been described to cause RP (https:
//sph.uth.edu/Retnet/; 29 July 2021). Of all RP cases, approximately 60% display an
autosomal recessive mode of inheritance (arRP) [3]. Mutations in Eyes shut homolog (EYS)
are a major contributor to arRP pathology, accounting for approximately 5–35% of all
cases [4–9], and are believed to act via a loss-of-function mechanism.
EYS is located on chromosome 6p12, spans over 2 Mb and is predominantly expressed
in the photoreceptor cells of the retina. The full-length transcript is comprised of 44 exons
which together encode the 3144 amino acids long protein eyes shut homolog (EYS). The EYS
protein domain architecture is predicted to contain 28 epidermal growth factor (EGF)(-like)
domains and five laminin G (LamG) domains [10,11] (Figure 1). So far, little is known
about the exact function of EYS and the molecular pathogenesis of the associated RP. The
EYS protein localizes to the photoreceptor ciliary axonemes and the outer plexiform and
ganglion cell layers [12]. However, based on the predicted protein domain architecture,
EYS appears to be an extracellular protein.
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Figure 1. Schematic representation of the domain architecture of human and zebrafish EYS proteins.
Both human and zebrafish EYS proteins are comprised of a repetitive protein domain architecture
that includes epidermal growth factor (EGF) domains, EGF-like domains and laminin G (LamG)
domains. Skipping of eys exon 40-44 results in the exclusion of one LamG and two EGF domains,
indicated with a dashed boxed. Numbers indicate amino acids.
Currently, no treatment for EYS-associated RP exists that can prevent disease progres-
sion or restore visual function. For therapy development, suitable cellular or animal models
that mimic the human phenotype are pivotal. With the recent developments in induced
pluripotent stem cell (iPSC) technology, it is now possible to reprogram iPSCs from easily
accessible patient cells (e.g., fibroblasts or PBMCs) and differentiate them into iPSC-derived
photoreceptor cells (iPSC-Ps) [13]. This allows the assessment of the molecular efficacy of
novel therapeutic strategies in the context of a patient’s own relevant molecular and cellular
environment. However, to evaluate the effect of potential therapies on visual function,
animal models are essential. Rodents, which are frequently used models for studying
IRDs [14], lost the Eys gene during evolution [11]. The zebrafish has emerged as an alterna-
tive and pre-eminent model to study IRDs, as they have a high fecundity, are amenable to
genetic manipulation, and have a retinal structure comparable to humans [14]. Previously,
two eys knock-out zebrafish models have been generated and characterized [15,16]. The
absence of Eys resulted in the loss of photoreceptor structural integrity and an impaired
retinal architecture, ultimately leading to mislocalisation of rhodopsin, a progressive de-
generation of the photoreceptor cells, and decreased ERG responses. We generated and
characterized a third zebrafish knock-out model which, in a dition to the previ usly de-
scribed phenotypic features, showed diminished locomotor activity in response to light
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stimuli [17]. Therefore, zebrafish can be regarded as an attractive model to evaluate the
potential of novel therapeutic strategies for EYS-associated RP.
The development of gene augmentation therapy for EYS-associated RP is severely
hampered by the size of the EYS-encoding sequence (9.4 kb). The protein-coding sequence
exceeds the 4.7 kb packaging capacity of adeno-associated virus (AAV) vehicles, which
are the currently preferred vehicles for retinal gene delivery [18]. An alternative therapeu-
tic approach, which has already proven its potential in several (pre-)clinical studies for
Usher syndrome, Duchenne muscular dystrophy, and CADASIL [3,19,20], is the antisense
oligonucleotide (AON)-based skipping of native, in-frame exons harboring recurrent loss-
of-function mutations. In this study, we therefore investigated the therapeutic potential
of exon skipping as a future treatment option for EYS-associated RP. In order to study
the long-term effect of this treatment modality in a controlled setting, we employed the
CRISPR/Cas9 system to generate stable zebrafish mutants from which the genomic region
that encompasses the orthologous exons of the frequently mutated human EYS exons
37-41 was specifically excised. Excision of this in-frame combination of exons, resulting
in the stable eys∆exon40-44 zebrafish line, was predicted to result in a transcript encoding a
shortened Eys protein that lacks exactly one evolutionary conserved repetitive module
consisting of one LamG and two EGF domains. We hypothesized that this protein has
sufficient residual function for maintaining vision.
2. Results
2.1. The C-Terminal Region of EYS Is Highly Conserved between Zebrafish and Man
We, and others, have previously generated and characterized zebrafish eys knock-
out mutants, and presented the zebrafish as a suitable model to study EYS-associated
retinal disease [15–17]. Our mutant, designated eysKO, displayed significantly reduced
electroretinogram (ERG) traces in the absence of the Eys protein [17]. To identify a potential
target region to assess the therapeutic potential of exon skipping as a future treatment
option, the conservation of the EYS exon structure and protein domain architecture between
human and zebrafish was analyzed (Figure 1). We previously reported an overall 33%
amino acid identity between human and zebrafish EYS [17]. Zebrafish Eys lacks the
so-called low-complexity central region, while the N-terminal EGF domains and EGF-
like domains are conserved. The EYS C-terminal region, starting directly after the low-
complexity region, and harboring repetitive modules of LamG and EGF domains, shows
the highest degree of amino acid conservation (49% identity).
Based on EYS amino acid conservation and the presence of multiple protein-truncating
mutations in RP patients, we selected exons 37-41 of human EYS as a target to assess the
therapeutic potential of exon skipping. EYS exons 37-41 encompass 843 nucleotides in the
EYS mRNA and are predicted to encode exactly one module consisting of one LamG and
two EGF domains. In total 18 unique loss-of function mutations have been reported in EYS
exons 37-41 (EYS LOVD mutation database, https://databases.lovd.nl/shared/genes/EYS;
27 July 2021). The length of the orthologous region in the zebrafish eys transcript (zebrafish
eys exons 40-44) is fully conserved, and the encoded protein region shows a 58% amino
acid identity. Similar to the human situation, the in-frame deletion of zebrafish eys exons
40-44 was predicted to result in a shortened protein (Eys∆exon40-44) from which exactly one
repetitive module consisting of one LamG and two EGF domains was lost. We hypothesized
that this protein has sufficient residual function for maintaining vision.
2.2. Eys Is Present at the Periciliary Membrane, Accessory Outer Segment, Connecting Cilium and
Ribbon Synapse of Zebrafish Photoreceptor Cells
In order to determine the exact subcellular localization of Eys in adult zebrafish
photoreceptor cells, we performed an immunoelectron microscopic analysis using the
previously published anti-Eys antibody [17]. Besides confirming the previously described
presence of Eys at the connecting cilium, we also detected Eys at the periciliary membrane,
cone accessory outer segment (AOS), and photoreceptor ribbon synapse (Figure 2). AOS
Int. J. Mol. Sci. 2021, 22, 9154 4 of 18
are structures that extend from the inner segments of cone photoreceptor cells of teleost fish,
run along the outer segments, and are mainly involved in retinomotor movements [21].
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Figure 2. Eys localization in adult zebrafish photoreceptor cells. Immunoelectron microscopy images of adult zebrafish
retinas show that Eys localizes at (A,B) the connecting cilium, periciliary membrane, cone accessory outer segments, and
(C,D) photoreceptor ribbon synapses. CC: connecting cilium, PCM: periciliary membrane, AOS: accessory outer segment,
IS: inner segment, OS: outer segment.
2.3. Generation of the eys∆exon40-44 Zebrafish Line Using CRISPR/Cas9 Technology
To investigate the therapeutic potential of exon skipping as a future treatment option
for EYS-associated RP, we adopted the CRISPR/Cas9 technology to generate a stable
zebrafish line from which the genomic region encompassing eys exons 40-44 was specifically
excised. For this, multiple sgRNAs were designed for the genomic regions upstream of eys
exon 40 and downstream of exon 44, and evaluated for their efficiency to cleave the target
DNA by injecting individual sgRNA-Cas9 complexes in fertilized embryos. The most
potent sgRNAs upstream of exon 40 and downstream of exon 44 were combined to excise
the genomic region in between. To avoid the preferential binding of Cas9 to either sgRNA,
individual sgRNA-Cas9 complexes were prepared and mixed together prior to injection. At
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1 dpf, 4 out of 16 injected embryos (25%) were screened positive for the anticipated lesion
by PCR analysis, and correct excision was confirmed by Sanger sequencing (Figure 3A).
The remainder of the injected founder embryos (F0) was raised into adulthood. Forty
embryos (8 pools of 5 embryos) of each potential founder were screened for germline
transmission by RT-PCR and Sanger sequencing. Germline transmission of the anticipated
lesion was identified in the progeny of 1 out of 12 screened F0 founder fish (Figure 3B).
To further reduce the incidence of potential off-target editing, the F1 fish harboring the
anticipated and sequence verified lesion was outcrossed once more with wild-type TL fish
(F2 generation), prior to the generation of the stable homozygous zebrafish eys exons 40-44
excision line, designated eys∆exon40-44. The homozygous eys∆exon40-44 fish were viable and no
abnormalities in their overall body morphology, development, or swimming behavior were
observed. Finally, PCR analysis and subsequent Sanger sequencing confirmed the absence
of any off-target editing events at three predicted off-target sequences with one nucleotide
mismatch as compared to the on-target sequence for the sgRNAs used [22] (Figure S1). Due
to strain-related differences in the DNA sequence between our zebrafish model (Tupfel
Longfin (TL)) and the reference sequence (Tuebingen (TU), assembly: GRCz11/danRer11),
one of the three predicted off-target sites had more mismatches with the sgRNA and lacked
the PAM-site.
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Figure 3. Characterization of the stable ys∆exon40-4 ze r fis line. (A) Schematic representation of
exon excision approach (upper panel). Sanger sequencing confirmed the presence of the anticipated
exons 40-44 excision in injected embryos (1 day post fertilization (dpf)); lower panel). (B) PCR
analysis identified germline transmission in 8 out of 8 pools of 1 dpf embryos obtained by breeding
an injected adult with a wild-type animal. PCR (+): positive PCR control, PCR (-): negative PCR
control.
2.4. eys∆exon40-44 Transcript Analysis
Total RNA was isolated from homozygous eys∆exon40-44 zebrafish larvae (n = 2) to
assess the effect of excision of the genomic region encompassing eys exons 40-44 on the tran-
scriptional level. RT-PCR analysis using a forward and reverse primer in respectively exons
38 and 46 of the zebrafish eys gene revealed a shortened PCR fragment in the eys∆exon40-44
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zebrafish in the absence of any clear alternatively spliced eys transcripts (Figure 4A). Sanger
sequencing confirmed that the eys∆exon40-44 larvae indeed express the expected eys transcript
lacking exons 40-44 (Figure 4B). In addition, long-range PCR analysis of the eys∆exon40-44
transcript, followed by PacBio® single-molecule long-read sequencing, did not reveal any
aberrant pre-mRNA splicing (Figure 4C) or CRISPR/Cas9-induced off-target modifications
within the eys coding sequence.
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ina of homozygous eysΔexon40-44 zebrafish, immunohistochemical analysis was performed 
using an antibody directed against the N-terminal region of the Eys protein on unfixed 
retinal cryosections of 5 dpf zebrafish larvae (Figure 5). Eys was previously shown to be 
present at the region of the photoreceptor connecting cilium, adjacent to the connecting 
cilium marker centrin [7,17]. As expected, Eys localized adjacent to centrin in strain- and 
age-matched wild-type larvae, and was absent in the photoreceptors of the eysKO larvae. 
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Figure 4. Transcript analysis of eys∆exon40-44 mRNA. (A) RT-PCR analysis revealed the absence of eys exons 40-44 in
eys∆exon40-44 larvae (5 days post fertilization (dpf)), in the absence of any clear alternatively spliced eys transcripts. (B) Sanger
sequencing of the eys∆exon40-44 amplicon confirmed the absence of exons 40-44 from the transcript. (C) Long-range PCR
analysis did not reveal any additional and unwanted amplicons derived from CRISPR/Cas9-induced alternative splicing of
eys transcripts. PCR (-): negative PCR control.
2.5. Eys Is Absent from the Retina of 5 dpf eys∆exon40-44 Zebrafish
To evaluate whether the excision of zebrafish eys exons 40-44 resulted in the generation
and correct subcellular localization of a shortened Eys protein (Eys∆exon40-44) in the retina of
homozygous eys∆exon40-44 zebrafish, immunohistochemical analysis was performed using
an antibody directed against the N-terminal region of the Eys protein on unfixed retinal
cryosections of 5 dpf zebrafish larvae (Figure 5). Eys was previously shown to be present at
the region of the photoreceptor connecting cilium, adjacent to the connecting cilium marker
centrin [7,17]. As expected, Eys localized adjacent to centrin in strain- and age-matched
wild-type larvae, and was absent in the photoreceptors of the eysKO larvae. Surprisingly,
like in the eysKO zebrafish, no Eys protein could be detected in the retinas of the eys∆exon40-44
larvae, indicating that the excision of exons 40-44 interferes with Eys protein expression
in the zebrafish retina. Although our predictions indicate that the epitope to which the
anti-Eys antibody is directed is not affected by the excision, it cannot be completely ruled
out that the antibody is not able to detect the Eys∆exon40-44 protein.
Int. J. Mol. Sci. 2021, 22, 9154 7 of 18
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Figure 5. Immunohistochemistry on retinal sections of wild-type, eysKO and eys∆exon40-44 zebrafish. Retinal cryosections of
wild-type, eysKO and eys∆exon40-44 larvae (5 days post fertilization (dpf)) stained with antibodies directed against Eys (red)
and centrin (green). Nuclei are counterstained with DAPI (blue). In eysKO and in eys∆ex40-44 zebrafish retinas no Eys signal
was detected, wher as in th retinas of wild-type larvae Eys was present adjacent to the centrin immunoreactivity. Scale bar:
10 µm. OS: outer segment, CC: connecting cilium, IS: inner segment, ONL: outer nuclear layer.
2.6. Disturbed Retinal Morphology and Disorganization of Photoreceptor Outer Segments in Adult
eys∆exon40-44 Zebrafish
Next, we evaluated whether or not the excision of eys exons 40-44 had an effect on the
overall retinal morphology. For this, retinal sections of adult zebrafish (15 months post
fertilization (mpf)) were stained with hematoxylin and eosin (HE) (Figure 6). Retinas of the
eys∆exon40-44 and eysKO lines appear to be morphologically indistinguishable. In both the
eys∆exon40-44 and eysKO retinas, a reduction in thickness of all retinal layers was observed
as compared to strain- and age-matched wild-types. In addition, photoreceptor outer
segments were shortened and disorganized in both the eys∆exon40-44 and eysKO zebrafish
as compared to wild-types. These data indicate that the eys∆exon40-44 line is phenotypically
highly similar to our previously published eysKO line [17].
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2.7. Impaired Locomotor Activity f eys∆exon40-44 Zebrafish in Response to Light
Although no sign of Eys∆exon40-44 express on was obtained and the retinal morphol-
ogy of the dult eys∆exon40-44 zebrafish was severely disturbed, the visual function of th
∆exon40-44 larvae w s assessed using visual motor res onse (VMR) measurements. The
wild-type, eysKO and eys∆exon40-44 larvae (5 dpf; n = 48; 3 biologic l replicates) w re ex-
posed to alternating periods of 50 min of darkness and 10 min of brig t light for a otal
of 5 cycles. We s c fically analyzed the distance moved during the first second aft r the
Light-ON trans tion, since this period is describe to contain the visual startl response [23]
(Figur 7A). The first tec nical Light-ON transition is excluded from the analysis si ce the
VMR res onse to this transition has been described to be altered by the difference in the
length of dark adaptation [24]. All larvae analyzed responded to the Light-ON transition,
however the response to light was less pronounced in the eysKO and eys∆exon40-44 larvae
as compared to the strain- and age-matched wild-type larvae. Overall, our data showed
that the distance moved was significantly lower in the eys∆exon40-44 larvae than in wild-type
larvae at two out of four Light-ON transitions (Figure S2; p < 0.05 and p < 0.001, respec-
tively). If we take the mean distance moved of the four Light-ON transitions per larva,
the distance moved was significantly lower in the eys∆exon40-44 larvae than in wild-type
larvae (Figure 7B; p < 0.0 01) Simultaneously, no significant difference in Light-ON VMR
was observed between eysKO and eys∆exon40-44 (Figure 7B, p > 0.05; Figure S2, p > 0.05),
indicating that the excision of eys exons 40-44 results in a similar visual function at 5 dpf as
observed in the eys knock-out model.
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Figure 7. Visual Motor Responses in wild-type, eysKO and eys∆exon40-44 zebrafish. (A) A represen-
tative eye-specific Light-ON Visual Motor Response (VMR) from a single trial, presented as the
distance moved (mm) per second, is shown for the time frame of 15 s prior to and after light alter-
nation. Note that the response to light is less pronounced in the eysKO and eys∆exon40-44 larvae as
compared to the strain- and age-match d wild-type larva (5 dpf; n = 16 per group). (B) The distance
moved (mm, mean of 4 Light-ON transitions p r larva) during the first second after the Light-ON
transition for wild-type, eysKO and eys∆exon40-44 zebrafish. The dist nce moved was significantly
lower in the eys∆exon40-44 larvae (2.04 mm ± 0.66 (mean ± SD, n = 48)) than in wild-type larvae
(2.72 mm ± 0.93 (mean ± SD, n = 48)), while no significant difference was observed between the
eysKO larvae (1.75 mm ± 0.57 (mean ± SD, n = 47)) and eys∆exon40-44 larvae (5 dpf; n= 47 larvae).
*** indicates p < 0.0001. Trials were conducted as 3 biological replicates containing all genotypes in
each trial.
3. Discussion
Mutations in EYS are among the most frequ nt caus s of non-syndromic arRP, accounting
for approximately 5–35% of all arRP cases in th European and Asi n population [5–8,25,26].
In ord r to invest gate the therapeutic poten ial f ex n skipping for the future tr a ment of
EYS-associated RP, we generat d nd characterized a stable zebrafish in from which
region conta ing the orthologous exons of the frequently mutated human EYS exo s 37-41,
zebrafish eys exons 40-44, as specifically excised rom the genome usi g the CRISPR/Cas9
system. The eys∆exon40-44 transcript level was found at levels comparable to hat of wild-type
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eys and no off-target modifications within the eys coding sequence could be detected by
single-molecule long-read transcript sequencing. However, the Eys∆exon40-44 protein could
not be detected at the region of the connecting cilium and visual motor response (VMR)
experiments revealed that the eys∆exon40-44 larvae were visually impaired. In addition,
retinal degeneration was observed in the adult eys∆exon40-44 zebrafish, similar to that in the
previously published eysKO zebrafish. Altogether, the data obtained in our zebrafish model
currently provide no indications for the skipping of EYS exons 37-41 as an effective future
treatment strategy for EYS-associated RP.
Since the initial publications in 2008 [10,11], many groups have reported on RP pa-
tients carrying mutations in EYS. However, limited data are available about the exact
function of EYS in the retina and the molecular defects in EYS-associated retinal disease. In
human Y79 retinoblastoma cells, EYS was identified in the cytoplasm and along the ciliary
axoneme [12]. Visualization of EYS in macaque retinal sections revealed EYS proteins in
whip-like structures along the photoreceptor ciliary axonemes and in the outer plexiform
and ganglion cell layers [12]. As such, EYS was suggested to fulfill a role in the structural
organization of the outer segments of mammalian photoreceptors. By performing immuno-
electron microscopy, we demonstrated that Eys localizes at the periciliary membrane, cone
AOS, connecting cilium and ribbon synapse of zebrafish photoreceptor cells. The exact
localization of Eys at the ribbon synapse remains unclear, but may point towards a role in
signal transduction. In adult teleost fish, AOS are suggested to provide structural support
to the outer segments and are suggested to be involved in the exchange of metabolites be-
tween RPE and cones by anchoring the cones to the RPE [21,27,28]. Based on comparisons
of ultra-structures of the mammalian and teleost photoreceptors, microtubule structures
along the mammalian outer segments were suggested to represent embedded AOS [27].
Our findings are therefore in line with the previously published localization of EYS in
whip-like structures along the macaque photoreceptor outer segments and support the
hypothesis of EYS to be essential for structural integrity of photoreceptor cells and main-
tenance of photoreceptor morphology in the mammalian and zebrafish retina [12,15–17].
Myosin VIIa and usherin, two other proteins in which mutations have been associated with
syndromic forms of RP, have also been shown to localize in the zebrafish cone AOS [21,29].
It is therefore tempting to speculate that these proteins could be involved in the same
cellular process, which, upon interruption due to the absence or dysfunction of one of the
proteins, might cause RP.
Based on the predicted EYS protein domain architecture, and contradictory to the
identified intracellular localization, an additional role for EYS in maintaining structural
integrity of the extracellular matrix can be suggested. Usherin and CRB proteins, which are
IRD-associated transmembrane proteins, have a somewhat similar protein domain struc-
ture compared to EYS, and harbor several EGF(-like) domains and LamG domains [29,30].
Usherin is part of a protein complex that provides protein support to the photoreceptor peri-
ciliary region [31]. CRB proteins are known to be involved in photoreceptor morphogenesis
and mechanisms that control cell adhesion, polarity, and intracellular communication [30].
This is in line with the previously identified functions of the individual EGF and LamG
domains [32,33]. In general, EGF domains and LamG domains are mainly found in the
extracellular parts of membrane-bound proteins or in proteins that are secreted, and are
amongst others involved in cell signaling and adhesion. In usherin, CRB1, CRB2, and
CRB3 the EGF and LamG domains are indeed present in their extracellular regions [29,30].
In contrast, EYS does not contain a transmembrane domain, but at the N-terminal region
of the EYS protein a signal peptide is predicted to be present, which might indicate that
the protein is secreted and, as such, involved in extracellular processes. It can be argued
that the identified intracellular Eys localization captures the translocation of Eys to the
extracellular space. Functional studies, for instance protein affinity chromatography and
yeast two hybrid assays, might enhance our insights in the function of EYS.
As EYS is thought to be essential for photoreceptor maintenance in humans, ther-
apeutic strategies that rescue the expression of functional EYS protein in the retina can
Int. J. Mol. Sci. 2021, 22, 9154 11 of 18
potentially preserve visual function in patients by preventing or slowing down the progres-
sion of photoreceptor degeneration. The eye is an easily accessible and immune-privileged
organ, which makes it suitable for therapeutic interventions. As such, several genetic thera-
pies for IRDs have reached the clinical phase or even obtained market approval. Patients
with RPE65-associated RP can now be treated with the first commercially available gene
augmentation therapy LUXTURNA™ (voretigene neparvovec-rzyl; Spark Therapeutics,
Inc., Philadelphia, PA, USA), which delivers a healthy copy of the RPE65 cDNA to the
retinal cells using an adeno-associated virus (AAV) [34,35]. Antisense oligonucleotides
(AON)-induced splice modulation therapies for several IRDs are also in the trajectory to
reach the market phase [36]. An advantage of the use of AONs over gene augmentation
therapy is that AONs can be more easily delivered. Their small sequence fits in an AAV
vector, enabling small nuclear RNA (snRNA)-based AON delivery [37]. snRNAs are com-
ponents of the small nuclear ribonucleoprotein complex (snRNP), which is involved in
histone pre-mRNA processing. The viral delivery of snRNAs with altered, target-specific
antisense sequences is now investigated as a versatile, long-term effective splice modu-
lation tool (#NCT04240315). Next to vector-based delivery, splice-modulation AONs can
also be delivered as naked molecules. Chemical modifications prevent those naked AONs
from RNAse H-based degradation and provide additional benefits to the AONs, such as
improved stability, bioavailability and an increased affinity to the target pre-mRNA [38].
AONs target the endogenously expressed pre-mRNA and are therefore not expected to
massively in- or decrease expression levels; a potential problem associated with gene
augmentation therapies.
Sepofarsen, which prevents the inclusion of a pseudo exon resulting from the frequent
c.2991+1655A>G mutation in CEP290, has been shown to be effective and safe in a phase
1/2 clinical trial (#NCT03140969) [39] and is currently under investigation in a phase 2/3
trial (#NCT03913143). Besides splice correction, AONs can also be used for the skipping
of native exons that harbor disease-causing mutations, provided that the skipping of the
respective exons does not affect the reading frame and that the exon does not encode a
domain crucial for protein structure or function. AON-mediated exon skipping has already
been shown to have a high therapeutic potential for large genes encoding (structural)
proteins that are built up by a series of repetitive protein domains, including usherin
and dystrophin [3,40]. The safety and therapeutic efficacy of AON-induced skipping
of native exons has been explored most thoroughly for Duchenne muscular dystrophy
(caused by mutations in the DMD gene), and two AON-based treatments have recently
obtained market approval by the FDA [41–45]. In the same way, QR-421a-based skipping
of USH2A exon 13 (642 bp) has already been successfully tested in a phase 1/2 clinical trial
(#NCT03780257) and two pivotal phase 2/3 clinical trials are currently being planned [3]. In
contrast to the previously mentioned DMD- and USH2A-related therapeutic exon skipping
strategies, the EYS region that we aimed to skip consists of multiple exons. In a study by
Aartsma-Rus et al. [46], AON-mediated co-skipping of DMD exon 43 and 44 resulted in the
restoration of dystrophin protein expression levels in patient myotubes, suggesting that a
double exon skipping approach is feasible. However, it remains to be determined whether
or not it is also possible to induce the simultaneous skipping of five exons.
Different from AON-induced exon skipping strategies, a CRISPR/Cas9-mediated
exon-excision strategy physically removes both the targeted exonic DNA regions and inter-
spaced intronic regions. This approach has recently been suggested by Pendse et al. [47]
as a potential treatment for USH2A-associated disease caused by mutations in exon 13.
In order to study the long-term effect of exon skipping as a future treatment option for
EYS-associated RP, we employed the CRISPR/Cas9 system to generate stable zebrafish
mutants from which the genomic region that encompasses the orthologous exons 37-41 of
human EYS (eys exons 40-44) was specifically excised. To our surprise, we could not detect
any Eys∆exon40-44 protein in the retina of the eys∆exon40-44 larvae. The eys∆exon40-44 transcript
seems to be present at levels comparable to wild-type eys, and the removed introns are not
located proximal to the promotor [48]. Although introns can influence transcript levels by
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affecting the rate of transcription, nuclear export, and transcript stability [49], the influence
of the removed introns on transcript levels is concluded to be negligible. Next to influencing
transcription, introns can also influence the efficiency of mRNA translation. One possible
explanation for the lack of Eys∆exon40-44 protein expression in the zebrafish retina could be
an altered secondary structure due to the loss of exons 40-44 from the mature transcript.
Erdmann-Pham et al. [50] showed translation to be a complex process that depends on
many parameters, including the traffic flow of ribosomes along the mRNA, sensitivity to
initiation rate changes, and efficiency of ribosome usage. The deletion of eys exons 40-44
from the transcript might influence translation efficiency, for example by blocking ribo-
somes from binding to the RNA due to an altered secondary structure, therewith limiting
translation initiation. In addition, the altered secondary structure might hamper the traffic
flow of the ribosomes along the mRNA, thus attenuating translation elongation. Another
possible explanation for the perceived absence of the Eys∆exon40-44 protein in the zebrafish
retina is the potential change in folding of the protein that interferes with the ability of
the antibody to detect the Eys∆exon40-44 protein. Although our predictions indicate that the
epitope to which the anti-Eys antibody is directed is not affected by the excision, it cannot
be completely ruled out that the antibody is not able to detect the Eys∆exon40-44 protein.
We previously performed a multiple sequence alignment using the EYS amino acid
sequences from different species and observed a high degree of conservation of the EYS
sequence and protein domain architecture [17]. Based on EYS amino acid conservation
and the presence of multiple protein-truncating mutations in RP patients [51], we selected
human EYS exons 37-41 as a target to assess the therapeutic potential of exon skipping.
However, an in-depth study on evolutionary conservation might provide more insight in
to which regions are essential for EYS protein expression and/or function. Perhaps the
regions that are poorly conserved or even absent in other species, such as zebrafish and
drosophila, are key to the function of EYS in the human photoreceptors. Alternatively, a
lack of conservation could indicate protein domains with biological functions that are not
selected for during evolution, and can therefore be missed in humans. In addition, long-
read sequencing technologies using tissue from healthy individuals might help to identify
naturally occurring alternative splicing events and shed light on which in-frame exons
can be missed without influencing protein expression or function. Vice versa, pathogenic
in-frame deletions or exon skipping events as a consequence of pathogenic variants also
indicate which (in-frame) exons are essential for protein expression or function [52].
We conclude that the genomic region that encompasses the orthologous exons of the
frequently mutated human EYS exons 37-41 is essential for Eys protein expression in the
zebrafish retina. The data obtained in our zebrafish model therefore currently provide no
indications for skipping of EYS exons 37-41 to be a feasible future treatment strategy for
EYS-associated RP. The zebrafish is a pre-eminent model to study IRDs as they have a high
fecundity, are amenable to genetic manipulation, and have a retinal structure comparable
to humans [14]. As previously published for USH2A-associated retinal degeneration, proof
of concept of exon-skipping therapy obtained in zebrafish has high translational value [3].
However, due to inter-species differences in the Eys protein and presence of translation
regulatory elements in the deleted intronic regions, the effect of AON-induced skipping
of exons 37-41 of human EYS on EYS expression and localization could be different. As a
next step, the analysis of EYS protein expression after AON- or CRISPR/Cas9-mediated
exon skipping in a suitable human cellular model (e.g., iPSC-derived 3D retinal organoids)
will determine the translational value of the results obtained from our zebrafish studies
and whether or not it is worthwhile to further explore this therapeutic approach using
alternative cellular or animal models.
4. Materials and Methods
4.1. Zebrafish Ethics, Maintenance and Husbandry
Animal experiments were conducted in accordance with the Dutch guidelines for
the care and use of laboratory animals (Wet op de Dierproeven 1996) and European
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regulations (Directive 86/609/EEC), with the approval of the Central Committee Animal
Experimentation (Centrale Commissie Dierproeven [CCD]) of the Royal Netherlands
Academy of Arts and Sciences (Koninklijke Nederlandse Akademie van Wetenschappen
[KNAW]) (Protocol #RU-DEC2016-0091). Wild-type Tupfel Longfin (TL) zebrafish and
the previously described eysrmc101/rmc101 mutants, here designated eysKO, were used [17].
Embryos were obtained from natural spawning. Zebrafish were maintained and raised
according to standard methods [53].
4.2. Multiple Sequence Alignment
A multiple sequence alignment of the C-terminal part of the human EYS protein
(encoded by exons 27-44; NM_001142800.1) and zebrafish Eys protein (encoded by exons
30-46) [17] was generated using AlignX in the Vector NTI software package (Vector NTI
Advance 11).
4.3. Fixation and Pre-Embedding Labeling for Immunoelectron Microscopy
For immunoelectron microscopy of adult zebrafish retinas, we followed the previ-
ously published protocol for pre-embedding labeling [29,54,55]. In brief, rabbit anti-EYS
(1:300; Novus Biologicals, Centennial, CO, USA, #NBP1-90038) was applied on vibratome
sections of pre-fixed (4% paraformaldehyde) dissected adult zebrafish eyes, followed by
incubation with biotinylated secondary antibodies. Antibody reactions were visualized by
a Vectastain ABC-Kit (Vector Laboratories, Burlingame, CA, USA) and a 0.01% hydrogen
peroxide to 0.05 M diaminobenzidine (DAB) solution was added. Stained retinas were
fixed in 2.5% glutaraldehyde in a 0.1 M cacodylate buffer (pH 7.4), followed by silver
enhancement of DAB precipitates and post-fixation in cacodylate buffered 0.5% OsO4 on
ice. Dehydrated specimens were flat-mounted between two sheaths of ACLAR-film (Ted
Pella Inc., Redding, CA, USA) in Araldite resin. Ultrathin sections were made using a
Reichert Ultracut S ultramicrotome (Leica, Wetzlar, Germany), collected on Formvar-coated
copper or nickel grids and counterstained with 2% uranyl acetate in 50% ethanol and aq.
2% lead citrate. Ultrathin sections were analyzed in a Tecnai 12 BioTwin transmission
electron microscope (FEI, Eindhoven, The Netherlands). Images were obtained with a
CCD camera (charge-coupled-device camera; SIS MegaView3; Surface Imaging Systems,
Herzogenrath, Germany) and processed with Adobe Photoshop CS (Adobe Systems).
4.4. CRISPR/Cas9 Genome-Editing Design
For genome editing, target sites were selected using the online web tool CHOP-
CHOP (https://chopchop.cbu.uib.no/; 27 July 2018) [56]. Single guide RNAs (sgRNAs)
were selected for synthesis based on the amount of predicted, off-target sites and by the
Doench et al. [57] predicted efficiency score. The synthesis of sgRNAs was performed
as described previously [58]. In brief, templates for in-vitro sgRNA transcription were
generated by annealing target-specific oligonucleotides containing the T7 promoter se-
quence (5′-TAATACGACTCACTATA-3′), the 20-base target sequence, and a region (5′-
GTTTTAGAGCTAGAAATAGCAAG-3′) complementary to a constant oligonucleotide
encoding the reverse complement of the tracrRNA tail. Phusion™ High-Fidelity DNA
Polymerase (New England Biolabs, Ipswich, MA, USA #M0530L) was used to fill the
ssDNA overhang, after which the template was purified using the GenElute™ PCR clean-
up kit (Sigma, Saint Louis, MO, USA, #NA1020-1KT). Transcription of the sgRNAs was
performed using the T7 MEGAshortscript™ Kit (Thermo Fisher, Waltham, MA, USA,
#AM1354). Obtained transcripts were purified using the MEGAclear™ Transcription
Clean-Up Kit (Thermo Fisher, Waltham, MA, USA, #AM1908). The oligonucleotides used
for sgRNA synthesis are listed in Table S1.
4.5. Microinjections
For the generation of the eys∆exon40-44 zebrafish (designated eysrmc9 in ZFIN), the 5′
sgRNA, 3′ sgRNA and commercial Alt-R® S.p. Cas9 Nuclease V3 (IDT, Coralville, IA,
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USA, #1081059) were co-injected. To avoid preferential in vivo binding of Cas9 to either
sgRNA, individual sgRNA-Cas9 complexes were prepared and mixed together prior to
injection. For this, the individual mixtures were incubated at 37◦C for 5 min, after which
they were combined prior to injection. The final injection mix contained 80 ng/µL 3′
sgRNA, 80 ng/µL 5′ sgRNA, 800 ng/µL Cas9 protein, 0.2 M KCl and 0.05% phenol red.
Injection needles (World Precision Instruments, Friedberg, Germany, #TW120F-3) were
prepared using a micropipette puller (Sutter Instrument Company, Novato, CA, USA,
Model P-97). Wild-type zebrafish embryos were collected after natural spawning and
injected at the single cell stage with 1 nL of injection mixture using a Pneumatic PicoPump
pv280 (World Precision Instruments, Friedberg, Germany). After injection, the embryos
were raised at 28.5 ◦C in an E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
and 0.33 mM MgSO4), and supplemented with 0.1% (v/v) methylene blue. At 1 day post
fertilization (dpf), part of the injected embryos (8 pools of 5 embryos) was analyzed for the
presence of the anticipated exon deletion using genomic PCR analysis. The remainder of
the injected embryos were raised to adulthood.
4.6. Genotyping
Genomic DNA was extracted from whole larvae (1 dpf) or caudal fin tissue from
adult zebrafish. Tissue was lysed in 25 µL (larvae) or 75 µL (fin tissue) lysis buffer (40 mM
NaOH, 0.2 mM EDTA) at 95 ◦C for 20 min. The lysed samples were diluted 10 times with
milli-Q water, after which 1 µL of the diluted sample was used as a DNA template in 2 PCR
reactions to amplify the wild-type zebrafish eys allele and the zebrafish eys∆exon40-44 allele,
and in 3 PCR reactions to screen the predicted off-target sequences containing 1 mismatch
as compared to the on-target sequence for both sgRNAs used. One nucleotide mismatch
off-target sequences is listed in Table S2. For PCR analysis, the Q5 High-Fidelity DNA
Polymerase kit (New England Biolabs, Ipswich, MA, USA, #M0491L) was employed. All
primer sequences are listed in Table S3. NEB Tm Calculator (https://tmcalculator.neb.
com/#!/main, 2 August 2018) was used to obtain primer annealing temperatures (Tm).
The cycling conditions were as follows: 98 ◦C for 2 min, 35 cycles of 98 ◦C for 10 s, Tm
for 20 s and 72 ◦C for 30 s, followed by a final 72 ◦C for 2 min. The presence or absence of
the eys∆exon40-44 allele and the absence of screened off-target mutations was confirmed by
Sanger sequencing.
4.7. Transcript Analysis
For eys∆exon40-44 transcript analysis, 2 eys∆exon40-44 or 2 wild-type larvae (5 dpf) were
pooled and snap frozen in liquid nitrogen and total RNA was isolated using the RNeasy®
Micro kit (Qiagen, Hilden, Germany #74004) according to manufacturer’s protocol. Sub-
sequently, 100 ng of total RNA was used as a template for cDNA synthesis using the
SuperScript™ IV Reverse Transcriptase kit (Thermo Fisher, Waltham, MA, USA, #18090200).
A fragment spanning the deleted exons of the eys gene was amplified from the synthesized
cDNA using Q5® High-Fidelity DNA Polymerase kit (New England Biolabs, Ipswich, MA,
USA #M0491L) and using a forward primer and a reverse primer located in exons 38 and 46
of the zebrafish eys gene, respectively. Primer sequences are listed in Table S3. The cycling
conditions were as follows: 98 ◦C for 1 min, 35 cycles of 98 ◦C for 10 s, 60 ◦C for 20 s and
72 ◦C for 30 s, followed by a final 72 ◦C for 5 min. Amplified fragments were separated on
a 1% agarose gel and sequence-verified by Sanger sequencing.
4.8. Targeted Transcript Sequencing
To exclude the presence of CRISPR/Cas9-induced off-target edits within the eys
coding sequence, pools of five eys∆exon40-44 or wild-type larvae (5 dpf) were snap frozen
in liquid nitrogen and total RNA was extracted using the NucleoSpin® RNAII Isolation
kit (Macherey-Nagel, Hœrdt, France, #740955.50) according to manufacturer’s protocol.
Subsequently, 1 µg of total RNA was used as a template for cDNA synthesis using the
SuperScript™ IV Reverse Transcriptase kit (Thermo Fisher, Waltham, MA, USA, #18090200)
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and oligo dT primers. To visualize potential CRISPR/Cas9-induced rearrangements, part
of the cDNA was amplified using Q5® High-Fidelity DNA Polymerase kit (New England
Biolabs, Ipswich, MA, USA #M0491L) and primers targeting the full length eys transcript
(exons 1-46). Part of the amplified eys exons 1-46 fragment was used as an input for a nested
PCR to increase the amount of the amplicon. All primer sequences are listed in Table S3. The
cycling conditions were as follows: 98 ◦C for 2 min, 35 cycles of 98 ◦C for 10 s, 67 ◦C (full-
length amplicon) or 65 ◦C (nested amplicon) for 20 s and 72 ◦C for 6 min, followed by a final
72 ◦C for 5 min. The concentrations of the wild-type and eys∆exon40-44 zebrafish amplicons
resulting from the nested PCR were determined using a Qubit fluorometer (Thermo Fisher,
Waltham, MA, USA). Subsequently, 500 ng of each amplicon was analyzed by PacBio®
single-molecule long-read sequencing. PacBio® SMRTbell barcoded libraries were prepared
according to protocol ‘Procedure and Checklist—Preparing SMRTbell Libraries using
PacBio Barcoded Adapters for Multiplex SMRT Sequencing’ (Pacific Biosciences, Menlo
Park, CA, USA, Part Number 100-538-700-02). SMRTbell barcoded libraries were loaded on
a 1 M SMRTcell and sequenced on the PacBio® Sequel I system (Pacific Biosciences, Menlo
Park, CA, USA). SMRT® Link version 10.0 software was used for demultiplexing and
High Fidelity (HiFi) CCS3 (Circular Consensus Sequencing) read generation and mapping.
Variant calling was performed using the JSI SeqNext version 5.1.0 Build 503 software.
4.9. Immunohistochemistry and Histology
Zebrafish eys∆exon40-44, eysKO and strain-matched wild-type larvae (5 dpf) were cry-
oprotected with 10% sucrose in PBS for 10 min prior to embedding in an OCT compound
(Sakura, Alphen aan den Rijn, The Netherlands, Tissue-Tek, #4583). After embedding, sam-
ples were snap frozen in liquid nitrogen-cooled isopentane and cryosectioned following
standard protocols. Cryosections (7 µm thickness along the lens/optic nerve axis) were
permeabilized for 20 min with 0.01% Tween-20 in PBS. Sections were rinsed 3 times for
5 min with PBS and blocked for 1 h with a blocking buffer (10% normal goat serum and
2% bovine serum albumin in PBS). The antibodies diluted in the blocking buffer were
incubated overnight at 4 ◦C. Secondary antibodies were also diluted in the blocking buffer
and incubated together with DAPI (1:8000; D1306; Thermo Fisher, Waltham, MA, USA)
for 1 h. Sections were post fixed with 4% paraformaldehyde for 5 min and mounted with
Prolong Gold Anti-fade (P36930; Thermo Fisher, Waltham, MA, USA,). The following
primary antibodies and dilutions were used: rabbit anti-EYS (1:300; Novus Biologicals,
Centennial, CO, USA, #NBP1-90038), mouse anti-centrin (1:500; Millipore, Burlington,
MA, USA; #04-1624). Secondary antibodies (Alexa Fluor 568 goat anti-rabbit (Thermo
Fisher, Waltham, MA, USA, #A11011) and Alexa Fluor 647 goat anti-mouse (Thermo Fisher,
Waltham, MA, USA, #A21237)) were used in a 1:800 dilution. Images were taken using
a Zeiss Axio Imager fluorescence microscope equipped with an AxioCam MRC5 camera
(Zeiss, Oberkochen, Germany). To asses adult retinal morphology, dissected adult eyes
(15 mpf) from homozygous eys∆exon40-44, eysKO and strain-matched wild-type controls were
fixed overnight at 4 ◦C using 4% paraformaldehyde, dehydrated in ascending methanol
series, transferred to 100% methanol for an overnight incubation, and rehydrated in a
descending methanol series to 0.1% PBS-Tween-20. Afterwards, the eyes were cryopro-
tected with 10% sucrose in 0.1% PBS-Tween-20 for 15 min, followed by 30% sucrose in 0.1%
PBS-Tween-20 for 1 h at room temperature. The larvae were then embedded in the OCT
compound ((Sakura, Alphen aan den Rijn, The Netherlands, Tissue-Tek, #4583) and frozen
in melting isopentane. Cryosections (7 µm thickness along the lens/optic nerve axis) were
stained with hematoxylin and eosin and analyzed using a Zeiss Axioskop light microscope
(Zeiss, Oberkochen, Germany).
4.10. Visual Motor Response Assay (VMR)
Locomotor activity in response to Light-ON transitions, also known as visual motor
response (VMR), was analyzed using EthoVision XT 14 software (Noldus Information
Technology BV, Wageningen, The Netherlands). Zebrafish larvae (5 dpf) were individually
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positioned into a 48-wells plate, containing 350 µL of E3 medium per well. The 48-wells
plate was placed in the DanioVision™ observation chamber (Noldus Information Tech-
nology BV, Wageningen, The Netherlands). After 1 h of dark adaption, the larvae were
exposed to 5 cycles of 50 min dark/10 min light (~14 lux). In each run, 16 eys∆exon40-44
larvae, 16 eysKO larvae, and 16 strain-matched control wild-type larvae were tested. In
all experiments, the larvae were subjected to locomotion analyses between 13:00–18:00
in a sound- and temperature-controlled (28 ◦C) behavioral testing room. The variable of
interest was the distance moved (mm) during the first second after the Light-ON transition.
The Graphpad Prism software (version 5.03 for Windows, GraphPad Software, San Diego,
CA, USA, www.graphpad.com) was employed to generate scatter plots, calculate mean
values and SD values, and perform statistical analysis. VMR data were analyzed using
one-way ANOVA using the Tukey method. Statistical significance was set at p < 0.05.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
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